Níveis séricos e imunoexpressão tecidual do marcador CA 19-9 no carcinoma colorretal e comprometimento linfonodal

Conteúdo do artigo principal

Mariane Martins Manso
Newton Eiji Kitamura
José Roberto Martins de Souza
José Eduardo Gonçalves
Leandro Luongo Matos
Ana Maria Amaral Antonio Mader
Vera Luiza Capelozzi
Jaques Waisberg

Resumo

Introdução: O carcinoma colorretal é uma das neoplasias mais incidentes nos países ocidentais. É controverso se os níveis séricos e a imunoexpressão tecidual do marcador tumoral CA 19-9 estão relacionados com o comprometimento linfonodal e com a invasão linfática no carcinoma colorretal. Casuística e métodos: Em 45 pacientes com carcinoma colorretal operados, o nível de CA19-9 pré-operatório e a imunoexpressão do CA19-9 no tecido neoplásico foram analisados. Valores de CA19-9 ≥ 37 UI/ml foram considerados aumentados. As amostras do tecido com carcinoma colorretal foram submetidas ao estudo imunoistoquímico, com anticorpo monoclonal anti-CA19-9. A intensidade de expressão do CA19-9 na neoplasia foi semiquantificada em leve (+/+++), moderada (++/+++), intensa (+++/+++) ou ausente. Foram comparados os níveis séricos e a imunoexpressão tecidual do marcador CA19-9 com o comprometimento linfonodal e a invasão linfática. Resultados: O nível sérico e a imunoexpressão tecidual do CA19-9 não se relacionaram significantemente com o comprometimento linfonodal (p = 0,49 e p = 0,45, respectivamente) ou com a invasão linfática (p = 0,12 e p = 0,74, respectivamente). Conclusões: O nível sérico e a imunoexpressão tecidual do CA19-9 não refletem o comprometimento linfonodal e a presença de invasão linfática no carcinoma colorretal.

Detalhes do artigo

Seção
Artigos Originais

Referências

Jantscheff P, Terraciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 2003;21(19):3638-46. http://dx.doi.org/10.1200/JCO.2003.55.135

Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância de Câncer: Estimativas 2008: incidência de câncer no Brasil. Disponível em: http://www.inca.gov.br. Acessado em 14 de maio de 2010.

Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55(2):138-42.

Ponz De Leon M, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R et al. Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study. Cancer. 1992;69(3):626-35. http://dx.doi.org/10.1002/1097-0142(19920201)69:3<626::AID-CNCR2820690305>3.0.CO;2-#

Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957-72. http://dx.doi.org/10.1007/BF01542654

Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H et al. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J Gastroenterol. 2001;36(3):166-72. http://dx.doi.org/10.1007/s005350170124

Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology. 2004;66(4):296-302. http://dx.doi.org/10.1159/000078330

Salces I, Vegh I, Rodriguez-Mu-oz S, Colina F, Pérez A, Soto S et al. Tissue CA19-9 content in colorectal adenomas and its value in the assessment of dysplasia. Rev Esp Enferm Dig. 2004;96(4):246-54. http://dx.doi.org/10.4321/S1130-01082004000400003

Morales-Gutiérrez C, Vegh I, Colina F, Gómez-Cámara A, Landa IJ, Ballesteros D et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination. Cancer. 1999;86(9):1675-81. http://dx.doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1675::AID-CNCR8>3.0.CO;2-9

Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi T et al. Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol. 2002;34(4):408-15. http://dx.doi.org/10.1097/00004836-200204000-00005

Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am J Gastroenterol. 1994;89(1):101-5.

Fischbach W, Mössner J. Tissue concentrations of CEA and CA 19-9 in the carcinogenesis of colorectal carcinoma exemplified by the adenomacarcinoma sequence. Res Exp Med. 1988;188(2):101-14. http://dx.doi.org/10.1007/BF01852266

Asai S, Watanabe T, Sakamoto J, Kiriyama K, Ito K, Akiyama S et al. Expression and prognostic indicators of type 1 and type 2 Lewis blood group antigens in colorectal cancers. Nippon Geka Gakkai Zasshi. 1994;95(10):753-62.

Franchi F, Pastore C, Izzo P, Calió E. CA19-9 in the monitoring of colorectal cancer after surgery. Med Oncol. 2001;18(3):237-8. http://dx.doi.org/10.1385/MO:18:3:237

Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66(4):238-43. http://dx.doi.org/10.1002/(SICI)1096-9098(199712)66:4<238::AID-JSO3>3.0.CO;2-C

Nozoe T, Rikimaru T, Mori E, Okuyama T, Takahashi I. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma. J Surg Oncol. 2006;94(2):132-7.

Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511-6. http://dx.doi.org/10.1002/cncr.10492

Tempero MA, Uchida E, Takasaki H, Burnett Da, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501-3.

Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today. 1994;24(6):518-25. http://dx.doi.org/10.1007/BF01884571

Nakayama T, Watanabe M, Teramoto T, Kitajima M. Slope analysis CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res. 1997;17(2B):1379-82.

Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-78.

Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124(2):169-74. http://dx.doi.org/10.1016/j.jss.2004.08.013

Duffy MJ, Van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-60. http://dx.doi.org/10.1016/j.ejca.2007.03.021

Akamine S, Nakagoe T, Sawai T, Tsuji T, Tanaka K, Hidaka S et al. Differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisª, sialyl Lewisx, and sialyl LewisTn antigens in serum and tumor tissue. Anticancer Res. 2004;24(4):2541-6.

Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki M et al. Expression of Lewis(a), sialyl Lewis(a), Lewis(x) and sialyl Lewis(x) antigens as prognostic factors in patients with colorectal cancer. Can J Gastroenterol. 2000;14(9):753-60.

Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL et al. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol. 2001;7(3):431-4.

Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53(2): 354-61.

Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456-66. http://dx.doi.org/10.1093/jnci/88.20.1456